Details for New Drug Application (NDA): 207050
✉ Email this page to a colleague
NDA 207050 describes BUSULFAN, which is a drug marketed by Accord Hlthcare Inc, Actavis, Am Regent, Amneal, Apotex, Arthur Grp, Eugia Pharma, Hospira, Meitheal, Mylan Institutional, Nexus, Norvium Bioscience, Pharmascience Inc, Prinston Inc, and Shilpa, and is included in fifteen NDAs. It is available from ten suppliers. Additional details are available on the BUSULFAN profile page.
The generic ingredient in BUSULFAN is busulfan. There are ten drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the busulfan profile page.
The generic ingredient in BUSULFAN is busulfan. There are ten drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the busulfan profile page.
Summary for 207050
| Tradename: | BUSULFAN |
| Applicant: | Pharmascience Inc |
| Ingredient: | busulfan |
| Patents: | 0 |
Pharmacology for NDA: 207050
| Mechanism of Action | Alkylating Activity |
Medical Subject Heading (MeSH) Categories for 207050
Suppliers and Packaging for NDA: 207050
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| BUSULFAN | busulfan | INJECTABLE;INJECTION | 207050 | ANDA | Sagent Pharmaceuticals | 25021-241 | 25021-241-10 | 8 VIAL in 1 CARTON (25021-241-10) / 10 mL in 1 VIAL |
| BUSULFAN | busulfan | INJECTABLE;INJECTION | 207050 | ANDA | Pharmascience Inc. | 51817-170 | 51817-170-01 | 8 VIAL in 1 PACKAGE (51817-170-01) / 10 mL in 1 VIAL |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 6MG/ML | ||||
| Approval Date: | Mar 24, 2017 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
